Visit Natera.com

Investor Relations

Set Up Alert

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
Learn More
 
Natera San Carlos

Stock Information

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Learn More

Recent News

August 4, 2021
Natera Announces Use of Signatera® as a Companion Diagnostic in GSK's Phase III ZEST Trial for Niraparib in Early-Stage Breast Cancer
AUSTIN, Texas , Aug. 4, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, announced that the first patient has been screened in a new phase III trial that uses its personalized, tumor-informed molecular residual disease (MRD) test, Signatera,
More
July 29, 2021
Natera Announces Second Quarter 2021 Earnings Conference Call
AUSTIN, Texas , July 29, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2021, after the market close on August 5, 2021.
More
July 28, 2021
New Study Validates the Signatera® MRD Test and Demonstrates its Clinical Utility in Early-Stage Esophageal Cancer
14th peer-reviewed Signatera paper with over 3,000 patients studied AUSTIN, Texas , July 28, 2021 /PRNewswire/ --  Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new peer-reviewed paper published in Gastroenterology validating its personalized
More
July 22, 2021
New Publication Shows 96% Overall Survival Among Metastatic Colorectal Cancer Patients Who Test MRD-Negative with Signatera® After Surgery
Data will be used to support submission to CMS for reimbursement, expanding Signatera's coverage beyond early-stage colorectal cancer AUSTIN, Texas , July 22, 2021 /PRNewswire/ --  Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the publication of a
More
July 22, 2021
Natera Announces Pricing of Follow-On Offering
AUSTIN, Texas , July 21, 2021 /PRNewswire/ --  Natera, Inc . (Nasdaq: NTRA), a pioneer and global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $113.00 per share.
More
Read More

Upcoming Events


Learn More

Past events

Read More

Recent Presentations

Learn More
The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.

Data Provided by Refinitiv. Minimum 15 minutes delayed.